KURA Teresa Brophy Bair sells $57K worth of shares
Mar 27, 2025, 10:32 AM
-10.15%
What does KURA do
Kura Oncology, headquartered in San Diego, focuses on developing precision medicines for cancer treatment, including small molecule candidates Ziftomenib, Tipifarnib, and KO-2806. The company went public in November 2015 and employs 142 staff.
Teresa Brophy Bair sold 7,281 shares of KURA on 28 January at $7.87 per share, worth a total of $57K. They now own 112,792 KURA shares, or a 6% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.